tiprankstipranks
Trending News
More News >

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.

Don’t Miss TipRanks’ Half-Year Sale

United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients.’ The study aims to evaluate the efficacy and safety of the drug Ralinepag, when added to standard care or specific background therapy, in patients with WHO Group 1 Pulmonary Arterial Hypertension (PAH). This study is significant as it could potentially improve treatment outcomes for PAH patients.

The intervention being tested is Ralinepag, an oral extended-release tablet, designed to enhance treatment for PAH. It is compared against a placebo to assess its effectiveness and safety.

The study is interventional, with a randomized, parallel assignment model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose of the study is treatment-focused.

The study began on August 30, 2018, with primary completion expected by June 23, 2025. The last update was submitted on June 23, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting the study’s progress and eventual results.

This update could influence United Therapeutics’ stock performance positively, as successful outcomes may enhance their market position in the PAH treatment space. Investors should also consider the competitive landscape, as advancements in PAH therapies could shift market dynamics.

The study is ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1